RiMINI – the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial

Peer Review reports

Original Submission
26 Aug 2015	Submitted	Original manuscript
12 Oct 2015	Reviewed	Reviewer Report - Amit Goel
14 Jan 2016	Author responded	Author comments - Christian Schulz
Resubmission - Version 2
14 Jan 2016	Submitted	Manuscript version 2
22 Jan 2016	Reviewed	Reviewer Report - Amit Goel
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
29 Jan 2016	Editorially accepted
29 Feb 2016	Article published	10.1186/s13063-016-1205-8

Back to article page